A phase-2 study suggested that patients with EGFR T790M mutation-positive advanced NSCLC with poor PS benefited from osimertinib treatment [11]; the PS improvement rate was > 70%, and nearly 90% of the patients improved from ≥ PS 3 at baseline to ≤ PS 2. This evidence concerns the gene EGFR and non-small cell lung carcinoma.